Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766727 | 0.72 | — | — | |
| SCHEMBL201430 | 0.71 | KMT2A (0.43) | ALDH1A1POLBKMT2ATLR8 | |
| SCHEMBL6767037 | 0.68 | ALDH1A1 (0.45) | ALDH1A1POLBKMT2ATLR8 | |
| SCHEMBL7972375 | 0.68 | KDM4E (0.33) | ALDH1A1POLBKMT2ATLR8 | |
| SCHEMBL18038297 | 0.66 | KMT2A (0.42) | ALDH1A1POLBKMT2ATLR8 | |
| SCHEMBL18038278 | 0.65 | ALDH1A1 (0.32) | ALDH1A1POLBKMT2ATLR8 | |
| SCHEMBL3065697 | 0.64 | ALDH1A1 (0.40) | ALDH1A1POLBKMT2ATLR8 | |
| SCHEMBL3171671 | 0.63 | CYP1A2 (0.32) | ALDH1A1POLBKMT2A | |
| SCHEMBL109668 | 0.62 | CYP2D6 (0.34) | ALDH1A1POLBKMT2A | |
| SCHEMBL18007731 | 0.61 | KMT2A (0.35) | ALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828320-B2 | Enzyme inhibitors; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-20020147214-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147214-A1 | Heterocyclic compounds | BRAF, ABL1, CSK | ALDH1A1 4024/4885POLB 1930/4885KMT2A 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.